TAGLN2 Human

Transgelin-2 has been proposed to act as an oncogenic factor, contributing to tumorigenesis in a wide range of human malignancies . Its ability to bind actin suggests that it may influence cell motility and structure, which are critical factors in cancer metastasis . Studies have shown that transgelin-2 is remarkably expressed in bone marrow-derived dendritic cells (BMDCs) during maturation and activation, indicating its potential role in cancer progression .

In addition to its oncogenic properties, transgelin-2 also plays a crucial role in the immune system . It is involved in the maturation and activation of dendritic cells, which are essential for initiating immune responses . Transgelin-2 knockout (Tagln2−/−) BMDCs exhibit significant defects in their ability to home to draining lymph nodes and prime T cells to produce antigen-specific T cell clones . These defects are associated with a failure to suppress tumor growth and metastasis in mouse models .

The therapeutic potential of transgelin-2 has been explored in the context of dendritic cell-based cancer immunotherapy . Non-viral transduction of cell-permeable, de-ubiquitinated recombinant transgelin-2 has been shown to enhance the functions of dendritic cells, thereby suppressing tumor growth and metastasis . This suggests that transgelin-2 can act as a double-edged sword, depending on how it is applied in cancer therapy .